Core Insights - The upcoming "15th Five-Year Plan" emphasizes the construction of a modern industrial system and the strengthening of the real economy as a strategic priority, focusing on the development of emerging and future industries [1][2] Emerging Industries - The plan aims to cultivate new pillar industries, accelerating the development of strategic emerging industry clusters such as new energy, new materials, aerospace, and low-altitude economy, potentially creating several trillion-yuan markets [2] - Future industries like quantum technology, biomanufacturing, hydrogen energy, nuclear fusion, brain-computer interfaces, and sixth-generation mobile communication are highlighted as new economic growth points [2][4] City-Level Developments - Cities like Beijing, Shanghai, and Shenzhen continue to lead in emerging industries, while newer cities like Hangzhou and Hefei are also making significant strides [3] - Hefei is recognized as a hub for quantum technology, housing nearly one-third of the country's quantum enterprises and establishing a complete ecosystem from research to industrialization [7] Quantum Technology - Hefei's quantum technology sector is experiencing a financing boom, with companies like Benyuan Quantum and Guo'an Quantum preparing for IPOs, indicating strong market interest [7] - The city is implementing a "technology innovation + scenario application" initiative, allocating at least 30 million yuan to develop urban and industrial scenarios [7] Biomanufacturing - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with competitive clusters emerging in cities like Shanghai, Beijing, and Shenzhen [9][10] - Shenzhen is becoming a highland for synthetic biology, with 40% of new synthetic biology enterprises established there in the past three years [10] Hydrogen and Nuclear Fusion - Hydrogen energy and nuclear fusion are identified as key future industries, with over 20 provinces outlining long-term plans for hydrogen energy development [14] - Chengdu and Hefei are leading in nuclear fusion research, with significant advancements in experimental conditions for fusion energy [15] Brain-Computer Interfaces - The brain-computer interface market is projected to reach approximately $2.62 billion by 2024, with cities like Beijing, Shanghai, Shenzhen, and Hangzhou taking the lead in developing this technology [16][20] - Policies are being implemented to foster a competitive ecosystem in brain-computer interfaces, aiming to cultivate globally influential enterprises by 2030 [19] Embodied Intelligence - The embodied intelligence market in China reached 418.6 billion yuan in 2023, with expectations for growth driven by advancements in AI technology [21][22] - Cities are competing to establish themselves as leaders in this sector, with Beijing and Shenzhen targeting the development of a trillion-yuan industry cluster by 2027 [22][23] Sixth-Generation Mobile Communication - Nanjing is emerging as a key player in the 6G sector, having established a comprehensive experimental platform and hosting significant industry events [26][27] - Traditional communication strongholds like Beijing and Shanghai continue to maintain their advantages while developing supportive policies for 6G applications [26][27]

Core Viewpoint - The company has terminated the planned acquisition of 55% of Shanghai CanShine Engineering Equipment Co., Ltd., which has drawn market attention, but this decision will not adversely affect its business operations or financial status [1][2]. Group 1: Acquisition Details - The acquisition was aimed at addressing core pain points in the biopharmaceutical sector and enhancing the company's strategic layout in this area [2]. - Shanghai CanShine possesses core capabilities in high-end biopharmaceuticals, including monoclonal antibodies and vaccines, which align well with the company's existing business [2]. - The termination of the acquisition was due to the inability to reach consensus on key terms, reflecting the company's commitment to shareholder interests and prudent decision-making [2][3]. Group 2: Strategic Focus - The company remains committed to its strategic focus in the semiconductor and biopharmaceutical sectors, emphasizing its modular overall solutions that meet overseas biopharmaceutical clients' needs for efficient delivery and compliance [3]. - Continuous investment in independent innovation has led to the establishment of a modular manufacturing base, supporting scalable and standardized development [3]. - The company plans to leverage favorable policies and market conditions to enhance its integrated solutions in biopharmaceutical cleanroom systems and core process systems, aiming to meet evolving customer demands and improve competitive strength [3].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪粉e r们，今天是高薪精品仪器职位专辑 哦！ 销售精英，热招职位 Ho t r e c r u itme n t p o siti o n s 培安 实验室通用仪器销售工程师 广州-8k-15k ·12薪 任职要求： 本科及以上学历，化学、药学、食品，生物等相关专业；了解实验室通用仪器、微波有机合成/多肽合成/制备色谱仪器、食品分 析仪器、石化分析与柱塞泵等科研类仪器，具备一定的销售经验；有独立管理客户和执行计划的能力，出色的人际交往和沟通能力，抗压性 好；能够适应出差，有明确的自我提升意愿及目标，自学能力强。 艾卡 销售项目经理 上海-10k-20k ·12薪 任 职要求 ： 化学或生物相关专业毕业，大专以上学历；3年以上仪器行业销售经验；丰富的销售、市场推广和沟通技巧(口头、书面)；深 入的产品知识、应用知识及经验；自信、能够自我激励、目标导向能力强、信守承诺；优秀的独立工作能力；乐于面对挑战，善于解决问 题；具有创新、"肯做"和团队合作精神；流利的中文和/或英文。 科哲 CRO ...

Group 1 - The second academic conference on bioreactor engineering and biomanufacturing was held in Shanghai, focusing on cutting-edge technologies and industry development in the field [1] - East China University of Science and Technology aims to seize opportunities in the biomanufacturing sector, enhancing research in fine chemicals, electronic chemicals, and new energy [1] - Advanced biomanufacturing is recognized as a disruptive technology that transcends traditional disciplines, necessitating a new foundational development logic [1][2] Group 2 - Bioreactors are identified as the "core engine" of biomanufacturing, with next-generation intelligent bioreactors expected to facilitate the efficient conversion of synthetic biology achievements [1] - The importance of bioreactor engineering in the industrialization of synthetic biology outcomes is emphasized, calling for enhanced collaboration between industry, academia, and research [1] - Key figures in the field discussed various topics, including the development of synthetic biology, the application of core materials in biopharmaceutical innovation, and the upgrade of the health industry driven by food and medicine integration [2]

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biotechnology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][3]. Group 1: Acquisition Details - The acquisition involves multiple investment entities, including PharmaLegacy Hong Kong Limited and several limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of this transaction [3]. Group 2: Regulatory Compliance - The transaction is in accordance with the "Major Asset Restructuring Management Measures" which stipulates that continuous purchases or sales of the same or related assets within twelve months must be cumulatively calculated [3][4]. - The assets involved in the transaction are recognized as belonging to the same or similar business scope, thus requiring inclusion in the cumulative calculation for this transaction [5]. Group 3: Financial Adjustments - The company has adjusted its capital increase plan for its subsidiary, increasing the planned investment from 20 million RMB to 5 million RMB, reflecting a strategic shift in resource allocation [4]. - The company has also made additional investments in other subsidiaries, such as a 42 million RMB increase in Suzhou Haixing Biotechnology Co., Ltd., acquiring a 30.0014% stake [4][5].